Vyne Therapeutics Inc (VYNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -5,622 | -23,210 | -13,265 | -3,806 | 4,670 |
| Depreciation Amortization | N/A | 72 | 227 | 56 | 44 |
| Accounts receivable | -200 | 11,210 | 8,048 | 8,215 | 7,984 |
| Other Working Capital | -712 | 2,277 | -1,665 | -2,615 | -1,651 |
| Other Operating Activity | 1,056 | -19,549 | -17,734 | -19,114 | -20,086 |
| Operating Cash Flow | $-5,478 | $-29,200 | $-24,389 | $-17,264 | $-9,039 |
| Cash Flows From Investing Activities | |||||
| Net Acquisitions | 5,000 | 15,667 | 15,666 | 15,752 | 15,752 |
| Investing Cash Flow | $5,000 | $15,667 | $15,666 | $15,752 | $15,752 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 156 | 1,470 | 1,471 | 1,471 | 1,557 |
| Other Financing Activity | -373 | 183 | -26 | 0 | -25 |
| Financing Cash Flow | $-217 | $1,653 | $1,445 | $1,471 | $1,532 |
| Beginning Cash Position | 30,975 | 42,855 | 42,855 | 42,855 | 42,855 |
| End Cash Position | 30,280 | 30,975 | 35,577 | 42,814 | 51,100 |
| Net Cash Flow | $-695 | $-11,880 | $-7,278 | $-41 | $8,245 |
| Free Cash Flow | |||||
| Operating Cash Flow | -5,478 | -29,200 | -24,389 | -17,264 | -9,039 |
| Free Cash Flow | -5,478 | -29,200 | -24,389 | -17,264 | -9,039 |